60 Degrees Pharmaceuticals, Inc. SXTP 深 滬
等待開盤 08-27 09:30:00 美东时间
1.27
-0.020
-1.55%
華盛通- 最 高1.2902
- 今 開1.29
- 成交量 2.48万股
- 最 低 1.26
- 昨 收 1.29
- 總市值 396.57万
- 52周最高 12.45
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 1.24
- 委 比 95.73%
- 總股本 312.26万
- 歷史最高 519.00
- 量 比 0.52
- 振 幅 2.34%
- 歷史最低 1.26
- 每 手 1
- 風險率 2.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced its participation in the 27th Annual Global Investment Conference hosted by H.C. Wainwright (HCW) from September 8-10, 2025, at the Lotte New York Palace Hotel. Dr. Geoff Dow, CEO, will present live on September 10, 2:30 ET, with management available for 1x1 meetings. The presentation will be webcast live and available for replay for 90 days. For more information, visit the investor...
08-21 12:31
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
60 Degrees Pharmaceuticals has signed a clinical trial agreement with Mount Sinai's Icahn School of Medicine to evaluate ARAKODA (tafenoquine) in treating chronic babesiosis, a debilitating illness with no FDA-approved treatment. The Phase II study will measure fatigue resolution in patients with at least six months of symptoms and assess the drug's safety and efficacy over 90 days. Enrollment is expected to commence in Q4 2025 and complete by Q2...
08-19 12:54
60 Degrees Q2 EPS $(1.25) Misses $(0.96) Estimate, Sales $101.000K Miss $301.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.96) by 30.21 percent. This is a 70.45 percent increase over losses of $(4.23) per share from the
08-14 04:19
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
60 Degrees Pharmaceuticals第二季度净产品收入同比下降19%，但因采用现金支付分销模式提高了盈利能力。公司拥有197万美元现金储备，预计可维持至2026年3月31日。尽管供应链中断影响了ARA-KODA 16盒装销量，但引入新的8盒装瓶和FDA批准的KODATEF 16盒装进口缓解了部分影响。公司还完成了几项商业研究，估计 babesiosis 的年度发病率在25,000至380,000例之间，预计未来10年内 ARK-O-D 的市场规模可能达到11亿美元。
08-13 20:14
60 Degrees Pharmaceuticals Secures $5M in Recent Offering
60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an announcement. On J...
07-19 05:17
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
60 Degrees Pharmaceuticals, Inc.与 Tulane University合作，启动研究评估tafenoquine对Borrelia（莱姆病）、Bartonella及Babesia（共同称为“3B”病原体）的活性。研究旨在探索tafenoquine治疗由这些病原体引发的共感染潜力。目前，tafenoquine获批用于疟疾预防，但尚未证明对 babesiosis 或Borrelia、Bartonella有效，也未获准用于这些适应症。
07-17 12:01
Market-Moving News for July 15th
TTD: 16% | The Trade Desk Will Replace Ansys In The S&P 500 Effective Prior To The Opening Of Trading On Friday, July 18 XAGE: 106% | Longevity Health Executes Definitive Merger Agreement With True
07-15 19:15
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
60 Degrees Pharmaceuticals announced the total addressable market (TAM) for ARAKODA (tafenoquine) in treating human babesiosis as 380,000 patients annually, with a sales potential of $245 million. This calculation is based on a nationwide survey of 6,000 patients and a study involving 300 healthcare professionals. The company plans to submit a New Drug Application (NDA) for babesiosis in 2026, contingent on positive data from three ongoing clinic...
07-15 11:01
60 Degrees Pharmaceuticals shares are trading higher after the company announced it will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species designation request to the FDA for tafenoquine for the treatment of acute canine babesiosis.
60 Degrees Pharmaceuticals shares are trading higher after the company announce...
07-15 04:04
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees Pharmaceuticals计划提交MUMS指定请求，基于三项临床研究结果，评估tafenoquine治疗犬巴贝斯虫病的潜力。目前，美国每年有数百至数千例犬巴贝斯虫病，但没有FDA批准的口服治疗方法。Tafenoquine已在疟疾预防中获批，但其在巴贝斯虫病治疗中的有效性需进一步研究。初步研究显示其耐受性良好，有助于急性感染恢复。
07-14 20:01
